The commitment to epithelial cell lineage upon stimulation of ovarian tumor cells with an optimal dose of epimorphin to induce MET leads to enhanced expression of several epithelial markers (e.g., β-catenin, occludin and EpCAM) and downregulation of mesenchymal markers (e.g., vimentin, dystroglycan, and palladin). The gene discussed is OCLN; the disease is ovarian neoplasm.